<DOC>
	<DOCNO>NCT00616772</DOCNO>
	<brief_summary>The primary purpose study test effect safety daily ABT-335 thickness line carotid artery ( blood vessel brain ) patient abnormal blood lipid optimal level low density lipoprotein cholesterol ( `` bad cholesterol '' ) take atorvastatin .</brief_summary>
	<brief_title>Safety Efficacy Study Using ABT-335 ( Investigational Drug ) Combination With Atorvastatin , Study Effects Thickening Blood Vessel Wall Patients With Abnormal Lipid ( Fat ) Levels Blood</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Choline</mesh_term>
	<criteria>Patients mixed dyslipidemia Qualifying cIMT thickness Patients certain chronic unstable medical condition . Patients unstable dose medication receive coumadin , cyclosporine , certain medication Pregnant lactate woman woman intend become pregnant Patients diabetes mellitus poorly control</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>